FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165029531> ?p ?o ?g. }

• W2165029531 endingPage "628.e4" @default.
• W2165029531 startingPage "610" @default.
• W2165029531 abstract "Canagliflozin is a sodium-glucose cotransporter 2 inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). Because T2DM is often associated with renal or hepatic impairment, understanding the effects of these comorbid conditions on the pharmacokinetics of canagliflozin, and further assessing its safety, in these special populations is essential. Two open-label studies evaluated the pharmacokinetics, pharmacodynamics (renal study only), and safety of canagliflozin in participants with hepatic or renal impairment.Participants in the hepatic study (8 in each group) were categorized based on their Child-Pugh score (normal hepatic function, mild impairment [Child-Pugh score of 5 or 6], and moderate impairment [Child-Pugh score of 7-9]) and received a single oral dose of canagliflozin 300 mg. Participants in the renal study (8 in each group) were categorized based on their creatinine clearance (CLCR) (normal renal function [CLCR ≥80 mL/min]; mild [CLCR 50 to <80 mL/min], moderate [CLCR 30 to <50 mL/min], or severe [CLCR <30 mL/min] renal impairment; and end-stage renal disease [ESRD]) and received a single oral dose of canagliflozin 200 mg; the exception was those with ESRD, who received 1 dose postdialysis and 1 dose predialysis (10 days later). Canagliflozin's pharmacokinetics and pharmacodynamics (urinary glucose excretion [UGE] and renal threshold for glucose excretion [RTG]) were assessed at predetermined time points.Mean maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to infinite (AUC)0-∞ values differed by <11% between the group with normal hepatic function and those with mild and moderate hepatic impairment. In the renal study, the mean Cmax values were 13%, 29%, and 29% higher and the mean AUC0-∞ values were 17%, 63%, and 50% higher in participants with mild, moderate, and severe renal impairment, respectively; values were similar in the ESRD group relative to the group with normal function, however. The amount of UGE declined as renal function decreased, whereas RTG was not suppressed to the same extent in the moderate to severe renal impairment groups (mean RTG, 93-97 mg/dL) compared with the mild impairment and normal function groups (mean RTG, 68-77 mg/dL).Canagliflozin's pharmacokinetics were not affected by mild or moderate hepatic impairment. Systemic exposure to canagliflozin increased in the renal impairment groups relative to participants with normal renal function. Pharmacodynamic response to canagliflozin, measured by using UGE and RTG, declined with increasing severity of renal impairment. A single oral dose of canagliflozin was well tolerated by participants in both studies. ClinicalTrials.gov identifiers: NCT01186588 and NCT01759576." @default.
• W2165029531 created "2016-06-24" @default.
• W2165029531 creator A5027581435 @default.
• W2165029531 creator A5028366409 @default.
• W2165029531 creator A5034243739 @default.
• W2165029531 creator A5036621224 @default.
• W2165029531 creator A5046780897 @default.
• W2165029531 creator A5047898874 @default.
• W2165029531 creator A5060450809 @default.
• W2165029531 creator A5060475451 @default.
• W2165029531 creator A5076233215 @default.
• W2165029531 creator A5083478319 @default.
• W2165029531 date "2015-03-01" @default.
• W2165029531 modified "2023-10-01" @default.
• W2165029531 title "Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor" @default.
• W2165029531 cites W1515542254 @default.
• W2165029531 cites W1550111394 @default.
• W2165029531 cites W1606165384 @default.
• W2165029531 cites W1899125083 @default.
• W2165029531 cites W1978656190 @default.
• W2165029531 cites W1982905493 @default.
• W2165029531 cites W1983989974 @default.
• W2165029531 cites W1988051941 @default.
• W2165029531 cites W1991671417 @default.
• W2165029531 cites W1996837305 @default.
• W2165029531 cites W1997018189 @default.
• W2165029531 cites W2000545769 @default.
• W2165029531 cites W2021988691 @default.
• W2165029531 cites W2026977556 @default.
• W2165029531 cites W2038270027 @default.
• W2165029531 cites W2040136554 @default.
• W2165029531 cites W2050614267 @default.
• W2165029531 cites W2055864845 @default.
• W2165029531 cites W2060123467 @default.
• W2165029531 cites W2067008718 @default.
• W2165029531 cites W2068171948 @default.
• W2165029531 cites W2069995779 @default.
• W2165029531 cites W2074989651 @default.
• W2165029531 cites W2077038286 @default.
• W2165029531 cites W2077071754 @default.
• W2165029531 cites W2077827708 @default.
• W2165029531 cites W2080051183 @default.
• W2165029531 cites W2084511068 @default.
• W2165029531 cites W2107412805 @default.
• W2165029531 cites W2112901207 @default.
• W2165029531 cites W2120919346 @default.
• W2165029531 cites W2121367181 @default.
• W2165029531 cites W2128982562 @default.
• W2165029531 cites W2130570549 @default.
• W2165029531 cites W2131135469 @default.
• W2165029531 cites W2133948398 @default.
• W2165029531 cites W2143329545 @default.
• W2165029531 cites W2146105386 @default.
• W2165029531 cites W2160471073 @default.
• W2165029531 cites W2162583290 @default.
• W2165029531 cites W2167984652 @default.
• W2165029531 cites W2168926920 @default.
• W2165029531 cites W2416046640 @default.
• W2165029531 cites W4210953420 @default.
• W2165029531 doi "https://doi.org/10.1016/j.clinthera.2014.12.013" @default.
• W2165029531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25659911" @default.
• W2165029531 hasPublicationYear "2015" @default.
• W2165029531 type Work @default.
• W2165029531 sameAs 2165029531 @default.
• W2165029531 citedByCount "34" @default.
• W2165029531 countsByYear W21650295312015 @default.
• W2165029531 countsByYear W21650295312016 @default.
• W2165029531 countsByYear W21650295312017 @default.
• W2165029531 countsByYear W21650295312019 @default.
• W2165029531 countsByYear W21650295312020 @default.
• W2165029531 countsByYear W21650295312021 @default.
• W2165029531 countsByYear W21650295312023 @default.
• W2165029531 crossrefType "journal-article" @default.
• W2165029531 hasAuthorship W2165029531A5027581435 @default.
• W2165029531 hasAuthorship W2165029531A5028366409 @default.
• W2165029531 hasAuthorship W2165029531A5034243739 @default.
• W2165029531 hasAuthorship W2165029531A5036621224 @default.
• W2165029531 hasAuthorship W2165029531A5046780897 @default.
• W2165029531 hasAuthorship W2165029531A5047898874 @default.
• W2165029531 hasAuthorship W2165029531A5060450809 @default.
• W2165029531 hasAuthorship W2165029531A5060475451 @default.
• W2165029531 hasAuthorship W2165029531A5076233215 @default.
• W2165029531 hasAuthorship W2165029531A5083478319 @default.
• W2165029531 hasConcept C111113717 @default.
• W2165029531 hasConcept C112705442 @default.
• W2165029531 hasConcept C126322002 @default.
• W2165029531 hasConcept C126894567 @default.
• W2165029531 hasConcept C134018914 @default.
• W2165029531 hasConcept C159641895 @default.
• W2165029531 hasConcept C161457703 @default.
• W2165029531 hasConcept C22979827 @default.
• W2165029531 hasConcept C2777180221 @default.
• W2165029531 hasConcept C2777451236 @default.
• W2165029531 hasConcept C2778653478 @default.
• W2165029531 hasConcept C555293320 @default.
• W2165029531 hasConcept C71924100 @default.
• W2165029531 hasConcept C98274493 @default.
• W2165029531 hasConceptScore W2165029531C111113717 @default.

• next